5 - 7 December 2019 International Convention Centre (ICC) Sydney

The VERVE Symposium in conjunction with LINC Australia program will incorporate a world renowned international faculty, with live cases from the University Hospital in Leipzig, Prince of Wales Private Hospital Sydney and the Mater Hospital Sydney. We are introducing a call for abstracts in the categories of original scientific research and challenging cases with a chance for individuals to join the faculty for a podium or e-poster presentation, providing endovascular techniques, peripheral, carotid, aortic and late breaking trial data and the opportunity for individuals to present their research.

ENDOVASCULAR MASTERCLASS AND GLOBAL EXPERT DISCUSSION FORUM

*Program subject to change
To view the session content, please click on the arrow to the right of the session.

Thursday 5 December 2019    Venue: Parkside Ballroom – Level 2
07:00 - 06:00 pm
Registration Desk Open

7:00 - 6:00

Venue – Parkside Ballroom Level 2

VERVE Symposium: Room 1
08:30 - 10:00 am
Session 1.1: The Paclitaxel Controversy: What We’ve Learned About Paclitaxel Over the Last 12-Months

8:30 - 10:00

Introductory Remarks
Ramon Varcoe

8:35 - 8:50

Drug Eluting Technology: What Was the Impact of the JAHA Meta-Analysis 1-Year Later
Marianne Brodmann

8:50 - 8:58

Paclitaxel Insights from the TOTAL IN.PACT Program
Peter Schneider

8:58 - 9:06

Is Drug Based Technology Appropriate for Claudicants, CLI and Dialysis Access?
Gary Ansel

9:06 - 9:14

Alternative Explanations for the Safety Signal: The Impact of Clinical Trial Design
Ramon Varcoe

Discussion

10:00 - 10:30 am
Morning Tea
10:30 - 12:00 pm
Session 1.2: Future Directions in SFA Treatment

10:30 - 12:00

What is the Role of Open Vascular Surgery in PAD disease in 2020: An Overview of Proposed Indications
Marianne Brodmann

10:30 - 10:40

Supera Interwoven Nitinol stent for the Treatment of Femoral and Popliteal arterial Disease
Damien Holdaway

10:30 - 10:38

The Role of Non-Drug Eluting Technologies for Fem-Pop Revascularization in Light of the Paclitaxal Data
Ravish Sachar

10:38 - 12:00

Discussion

12:00 - 12:40 pm
Lunch
12:45 - 02:15 pm
Session 1.3: Pioneering Techniques in Aortoiliac Occlusive Disease

New Technical Developments in Stenting of the Abdominal Aorta and Common lliac Arteries for Steno-Occlusive Disease
Jos Van den Berg

10:53 - 11:01

A Prospective Registry for the Treatment of lliac Occlusions with Bare Metal Stent: 2-Year Outcomes
Yann Gouëffic

11:01 - 11:09

Endografts for Complex Aortoiliac Occlusions
Darren Schneider

11:09 - 11:18

An Update of the VBX Program in Aortoiliac Occlusive Disease
Andrew Holden

11:34 - 2:15

Discussion

02:15 - 03:45 pm
Session 1.4: Beyond Simple Drug Elution: A Combination of Endovascular Tools to Optimise Outcomes

The Art of Plaque Modification for Achieving Best Results in the SFA
Ravish Sachar

12:45 - 12:53

Atherectomy: How to Choose the Best Option, Avoid Problems and Bail Yourself Out
Andrew Bullen

12:53 - 1:13

Directional Atherectomy for the SFA and Popliteal Arteries
Domenic Robinson

1:13 - 1:21

The Evidence for Hyperbaric Oxygen Therapy in Patients with Diabetes-Related Foot Ulcers
Jonathan Golledge

1:29 - 1:37

An Australian Experience Using Combination Therapy Below the Knee
Vik Puttaswamy

2:03 - 3:45

Discussion

03:45 - 04:00 pm
Afternoon Tea
04:00 - 05:30 pm
Session 1.5: The Last Frontier of the Aortic Arch

The New C-Tag with Active Controlled Deployment is a Game Changer for TEVAR and Well Suited to the Aortic Arch
Hence Verhagen

4:00 - 4:08

Recorded Case: Aortic Arch and Descending TEVAR
Hence Verhagen

4:08 - 4:16

Treating Concomitant Disease of the Arch and Thoracic Aorta
Eric Verhoeven

4:16 - 4:36

Key Strategies to Prevent Retrograde Type A Dissection During TEVAR
Frank Criado

4:36 - 4:44

Endovascular Repair of the Ascending and Aortic Arch
Tilo Kolbel

4:44 - 4:52

Coronary Artery Bypass Grafting (CABG) combined with concomitant endovascular Hybrid repair of Aortic Arch Aneurysms.
Ramesh Tripathi

4:52 - 5:00

CTAG with Active Control: Conformable, Controlled, Predictable 
Eric Ducasse

5:31 - 5:30

Discussion

05:45 pm
Close of Day 1
05:45 - 07:00 pm
Welcome Reception

5:45 - 7:00

Venue: Parkside Ballroom

VERVE Symposium: Room 2
08:30 - 10:00 am
Session 2.1: Updates in Abdominal Aortic Aneurysm Treatment

8:30 - 10:00

Introductory Remarks
Hence Verhangen

8:30 - 8:35

These are the Current Unmet Needs in AAA Treatment
Frank Criado

8:35 - 8:43

EVAR is Associated with Increased Risk in Patients with Increased Luminal Space (Not Sac Diameter)
Hence Verhagen

8:43 - 8:51

Treatment Options for Type II Endoleak
Marc Schermerhorn

8:51 - 8:59

Outcomes after Endovascular Aneurysm Sealing (EVAS) in 298 Patients
Peter Holt

8:59 - 9:07

Right axillary access is effective and safe for Complex EVAR, ChEVAR and FEVAR
Ross Milner

9:07 - 9:15

CO² Imaging Use in PAD and EVAR Treatment. It Really Works!
Eric Ducasse

9:15 - 10:00

Discussion

10:00 - 10:30 am
Morning Tea
10:30 - 12:40 pm
Session 2.2: Issues and Controversy in Major Vein Disorders

Have Venous Stent Trials Revealed Any New Data?
Mahmood Razavi

10:30 - 10:40

What to do with disastrous inflow in post thrombotic ilio-femoral venous reconstruction
Gerard O’Sullivan

10:40 - 10:50

Failure modes of lliac veins stents and what we can do about them
Ramesh Tripathi

10:50 - 11:00

Treatment of Venous Thoracic Outlet Syndrome Using Angiojet, Rib Resection and Vein Patch Reconstruction
Tam Nguyen

11:00 - 11:10

Strategies for Managing Central Venous Occlusions
Mahmood Razavi

11:10 - 11:20

Pulmonary Artery Angioplasty in Chronic Pulmonary Hypertension Secondary to Previous PE
Sanjay Nadkarni

11:20 - 11:30

Real Patient Stories of Surviving DVT and PE
Laurencia Villalba

11:30 - 12:40

Discussion

12:00 - 12:45 pm
Lunch
12:45 - 02:15 pm
Session 2.3: Ultrasound Session I: The Value of Ultrasound in Complementing Procedural Vascular Care

12:45 - 12:45

Doppler Angle Correction in Vascular Sonography
Teal Derboghossian

New Ultrasound Technologies: V-Flow
Tricia Mares

How to Set‐up and Perform Contrast ‐ Enhanced Ultrasound
Gerry Hill

IVUS Guided Viabahn Stentgraft Implantation for the Most Complex Femoropopliteal Lesions
Osamu Iida

Takayasu’s in a Young Female Patient: Case study
Daniel Cai

Scanning Protocol of an Athlete with Claudication: Case Study of Endofibrosis
Jiawei (Andy) Yang

12:45 - 12:55

Atypical Duplex Findings Following Aneurysm Surgery
Ian Catchpole

12:55 - 2:15

Discussion

02:15 - 03:45 pm
Session 2.4: EVAR and Challenging Anatomy

Experience with the Gore Excluder graft in More than 300 cases: Does Off IFU Matter?
Eric Verhoeven

2:15 - 2:23

How the Endurant Graft Improves My Ability to Treat More Challenging Aortic Necks with Good Long-Term Outcomes
Ross Milner

2:23 - 2:31

The Use of EVAR for the Treatment of Mycotic Aneurysms
Mathew Sebastian

2:31 - 2:39

Tips and Tricks for a Perfect Physician Modified Fenestrated Endograft when Required
Eric Ducasse

2:39 - 2:47

FEVAR and BEVAR for the Management of Failed EVAR
Darren Schneider

2:47 - 3:45

Discussion

03:45 - 04:00 pm
Afternoon Tea
04:00 - 05:30 pm
Session 2.5: The Challenges of Limb Salvage in Advanced BTK Disease

Rutherford 6 wounds – the utility of multi-vessel revascularization and inflow strategies
Peter Schneider

4:00 - 4:10

The Technique of Distal Puncture for BTK Occlusion
Tatsuya Nakama

4:10 - 4:20

Using Rotarex in BTK Arteries: Where Can it be Used Most Safely and Effectively
Sven Bräunlich

4:30 - 4:40

Does the Downstream Effect After Drug-Coated Balloon Treatment Impact Time to Wound Healing in CLI?
Osamu Iida

4:40 - 4:50

How Best to Define and Treat “No Option” CLI Patients
Marianne Brodmann

5:00 - 5:10

Venous Arterialization for Patients with Recurrent TLR Facing Possible Amputation: Results from a Single Center Observational Study
Jihad Mustapha

5:10 - 5:20

The Unrealized Potential of Effective Medical Management in People with Peripheral Artery Disease
Jonathan Golledge

5:20 - 5:30

Discussion

05:45 pm
Close of Day 1
05:45 - 07:00 pm
Welcome Reception

5:45 - 7:00

Venue: Parkside Ballroom

Friday 6 December 2019    Venue: Parkside Ballroom – Level 2
07:00 - 06:00 pm
Registration Desk Open

7:00 - 6:00

Venue – Parkside Ballroom Level 2

VERVE Symposium: Room 1
08:00 - 09:30 am
Session 1.6: Latest Clinical Trial Releases and Advances in PAD Treatment

French Guidelines for the Management of Ambulatory Endovascular Procedures for Lower Extremity Peripheral Artery Disease
Yann Gouëffic

8:00 - 8:08

SAVAL BTK Trial Update: Unique Stent Technology for Complex Tibial Anatomy
Jihad Mustapha

8:08 - 8:28

The Cost Effectiveness of Angiojet in Treating Acute Limb Ischemia 
Laurencia Villalba

Final Results of the Ranger II Pivotal Trial
Ravish Sachar

8:28 - 9:30

Discussion

09:30 - 11:00 am
Session 1.7: Complex PAD Lesions and New Clinical Trial Data

An Update on the Lutonix PAD Global Registry
Sven Bräunlich

9:30 - 9:38

The Value of Atherectomy in CLI Interventions
Giancarlo Biamino

9:38 - 10:00

The Lutonix BTK Trial 1-Year Update: Which Direction Should These Results Take Us?
Jihad Mustapha

10:00 - 10:08

The Treatment of Embolic Complications in Peripheral Vascular Interventions
Jos Van den Berg

10:08 - 11:00

Discussion

11:00 - 11:30 am
Morning Tea
11:30 - 01:00 pm
Session 1.8: Thoracic Aortic Aneurysms and Dissection

Update from the Valiant Navion clinical trial: A New Generation of TEVAR device
Ross Milner

11:30 - 11:38

Chronic Dissection and False Lumen Occlusion Techniques
Tilo Kolbel

11:38 - 12:00

Setting up a Thoracoabdominal Program in an Australian Teaching Hospital
Raffi Qasabian

12:00 - 12:08

What is the Stroke Risk from Complex EVAR and TEVAR: Real World Data from the VQI
Marc Schermerhorn

12:08 - 12:16

An Update of the Treatment of Chronic Dissections
Eric Verhoeven

12:16 - 12:24

Update on Thoracic IMH: Further insights on its nature and indications for intervention
Frank Criado

12:24 - 1:00

Discussion

01:00 - 02:00 pm
Lunch
02:00 - 03:30 pm
Session 1.9: Advanced Concepts in Deep Venous Disease

MRV, Direct and Indirect CTV – When, Which and Why?
Gerard O’Sullivan

2:00 - 2:08

Deep Venous In-Stent Restenosis: Pathological Evidence as to its Cellular Origins
Cameron Robertson

2:08 - 2:30

Endophlebectomy And lliac Vein Stent Placement – How I Do It (Video Technique Demonstration) 
Ramesh Tripathi

2:30 - 2:38

Results from an Australian Venous Stenting Program
Phil Puckridge

2:38 - 2:54

Latest Update from the VERNACULAR Trial
Steven Dubenec

2:54 - 3:30

Discussion

03:30 - 04:00 pm
Afternoon Tea
04:00 - 06:00 pm
Session 1.10: Controversies in Aortic Aneurysm Management, Druability of EVAR and the Effect of Volume

What’s the Role of Open AAA Surgery in 2020 and Beyond?
Hence Verhagen

4:00 - 4:10

Does Operator Volume Make a Difference to Outcomes after Elective and Emergency Aortic Surgery? Results from the Australasian Vascular Audit
Ramon Varcoe

4:10 - 4:20

An International Comparison of AAA Treatment Rates Across Nine Countries
Peter Holt

4:20 - 4:30

EVAR vs Open Surgical Repair: How Do we Choose the Right Option for Any Given Patient
Marc Schermerhorn

4:30 - 4:40

Centralisation versus Proctoring for Fenestrated and Branched Aortic Stent Grafting: Which Provides Better Outcomes?
Eric Verhoeven

4:40 - 4:50

DEBATE: Centralization of Elective AAA Results in Safer Surgery with Lower Perioperative Risk
FOR the motion: Peter Holt
AGAINST the motion: Irwin Mohan

4:50 - 6:00

Discussion

06:00 pm
Close of Day 2
07:30 - 11:00 pm
Symposium Dinner

7:30 - 11:00

Venue: Sergeants Mess, Chowder Bay

Transfers to and from the venue

VERVE Symposium: Room 2
08:00 - 09:30 am
Session 2.6: Advanced Concepts in AAA Treatment

Computational Analysis of Seal Zone Preservation and Migration Resistance with EndoAnchors
Ross Milner

8:00 - 8:08

Heli-FX: Mid-term results from the ANCHOR Registry: How EndoAnchors Expand EVAR Patient Applicability
Venu Bhamidi

Complications Whilst Waiting for F/BEVAR Stent-Grafts: The Results Might Surprise You
Eric Verhoeven

8:08 - 8:28

The IBE: With a Dedicated IIA Component Which Shows Excellent Patency Data
Eric Ducasse

8:28 - 8:35

Techniques to Extend the Applicability of lliac Branch Devices
Darren Schneider

8:35 - 8:43

Dealing with the pending vascular surgery shortage in a multi-institutional vascular institute
Gary Ansel

8:43 - 9:30

Discussion

09:30 - 11:00 am
Session 2.7: Ultrasound Session 2: A New Horizon for Vascular Ultrasound

Recommendations & Reality of Infection Protection in the vascular imaging department
Veronica Hanrhan

9:30 - 9:40

Experience with Ultrasound Guided Tibial Angioplasty
Jihad Mustapha

9:40 - 9:50

IVUS in Deep Venous Reconstruction for Beginners
Gerard O’Sullivan

9:50 - 10:00

llio-Femoral Obstructions: Can We Improve Detection Rates?
Dan Rae

10:00 - 10:10

Duplex Findings in Unusual Venous Pathology
Ian Catchpole

10:10 - 10:20

What the! – Unusual Arterial Pathologies
Warren Lewis

10:20 - 11:00

Discussion

11:00 - 11:30 am
Morning Tea
11:30 - 01:00 pm
Session 2.8: The Paclitaxel Controversy Continues

A Summary of the VIVA Vascular Leaders Forum
Gary Ansel

11:30 - 11:38

Paclitaxel – Is it safe and how should we use it in PAD patients?
Peter Schneider

11:38 - 11:46

Long-Term Results from the IN.PACT Japan Trial
Osamu Iida

11:46 - 11:54

5 year data from the Asian DCB studies show superiority in mortality to POBA. What has gone wrong in the eastern part of the world
Jihad Mustapha

11:54 - 12:04

The Impact of Dose on the Paclitaxel Issue
Andrew Holden

12:04 - 12:12

Are There Alternatives to Paclitaxel? Different Immunosuppressive Drugs to Prevent Restenosis
Marianne Brodmann

12:12 - 1:00

Discussion

01:00 - 02:00 pm
Lunch
02:00 - 03:30 pm
Session 2.9: New Horizons in Dialysis Access Intervention

Latest Data From the LUTONIX DCB in AVF Trial
Gerard Goh

2:00 - 2:08

Update of the In.Pact AV Access RCT – Primary Endpoint and Sub-group Analysis
Andrew Holden

Mortality After DCB Use in the Failing AVF: A Meta-Analysis of RCTs
Krystal Dinh

2:08 - 2:28

Forced Maturation of the Arteriovenous Fistula Using Nitinol Stents
Shannon Thomas

2:28 - 3:30

Discussion

03:30 - 04:00 pm
Afternoon Tea
04:00 - 06:00 pm
Session 2.10: New Technology with the Potential to Improve Outcomes in PAD Treatment

New Devices and Innovations for Managing CLI
Peter Schneider

4:08 - 4:33

Intravascular lithoplasty: Study Status (DISRUPT PAD II and III) and Lessons Learnt from a Real-World Registry
Andrew Holden

4:00 - 4:08

The Various Approaches to Femoro-Popliteal CTOs: From $ to $$$
Gary Ansel

4:33 - 4:41

What Does it Mean “No option CLI”? : The Possibility of Percutaneous Deep Venous Arterialization
Tatsuya Nakama

4:41 - 4:49

The Role of a New Generation of Stem Cell Trials in Patients with CLI
Marianne Brodmann

4:49 - 4:57

Optimal Trial Design for Novel Therapies in CLI Patients
Mahmood Razavi

4:57 - 6:00

Discussion

06:00 pm
Close of Day 2
07:30 - 11:00 pm
Symposium Dinner

7:30 - 11:00

Venue: Sergeants Mess, Chowder Bay

Transfers to and from the venue

Saturday 7 December 2019    Venue: Parkside Ballroom – Level 2
07:00 - 06:00 pm
Registration Desk Open

7:00 - 6:00

Venue – Parkside Ballroom Level 2

VERVE Symposium: Room 1
08:00 - 09:30 am
Session 1.11: The Current State of Anti-Restenotic Therapy for the SFA

8:00 - 9:30

The BATTLE Trial: A RCT Comparing a Bare Metal Stent versus Paclitaxel Polymer Free Eluting Stent: 2-Year Outcomes
Yann Gouëffic

8:00 - 8:08

Latest Results from the REAL PTX Randomized Trial
Sven Bräunlich

8:08 - 8:38

Why we need to be scientific in our evaluation of pedal access utilization
Gary Ansel

8:38 - 9:30

Discussion

09:30 - 11:00 am
Session 1.12 The BTK Challenges Just Keep Coming

Advanced Interventional Techniques to Conquer the Recalcitrant CTO: Has to Achieve 100% Technical Success
Sven Bräunlich

9:30 - 9:38

Approaches after Failed CTO Crossing
Mahmood Razavi

9:38 - 9:58

The Use of Specialty Balloons in the BTK Segment
Jos Van den Berg

9:58 - 10:06

Distal Bypasses Have An Important Role In The Treatment Of CLTI In The Endovascular Era: What Is That Role ?  
Ramesh Tripathi

10:06 - 11:00

Discussion

11:00 - 11:30 am
Morning Tea
11:30 - 01:00 pm
Session 1.13: The Final Word on AAA

Technical Lessons Learned in Over 1400 Fenestrated and Branched EVAR Cases
Eric Verhoeven

11:30 - 11:38

Combination Approach with fEVAR and chEVAR for Selected Anatomies
Eric Ducasse

11:38 - 11:46

Survival after EVAR in octogenarians is similar to a matched control group without an aortic aneurysm from the general population
Hence Verhagen

11:46 - 12:06

Entirely Percutaneous Approaches to Complex EVAR
Darren Schneider

12:06 - 12:14

Long-Term Follow-up from a Single-Surgeon, Data-Linkage Study in 180 Consecutive Patients with Abdominal Aortic Aneurysm Treated with the Endurant Stent Graft System
Glen Benveniste

12:14 - 12:22

New Vascular Imaging Techniques: What Interventionalists Need to Know
Jos Van den Berg

12:22 - 12:30

Most truly inoperable aneurysm patients should be left alone, without repair – regardless of aneurysm size
Frank Criado

12:30 - 12:38

Evolution in Special Forces Trauma Training and Trauma Care/Surgery Since Afghanistan and Iraq
Jim lliopoulos

12:38 - 1:00

Discussion

01:00 - 02:00 pm
Lunch
02:00 - 03:30 pm
Session 1.14: Worst Ever Disasters

My Worst Ever Disaster…From Rotterdam
Hence Verhagen

2:00 - 2:10

My Worst Ever Disaster…From Sydney
Shannon Thomas

2:10 - 2:20

My Worst Ever Disaster…From Galway
Gerard O’Sullivan

2:20 - 2:30

My Worst Ever Disaster…From Tokyo
Tatsuya Nakama

2:30 - 2:40

My Worst Ever Disaster…From Lugano
Jos Van den Berg

2:40 - 2:50

My Worst Ever Disaster…From Nuremberg
Eric Verhoeven

2:50 - 3:30

Discussion

03:30 - 05:00 pm
Session 1.15 Challenging Case Presentations: Aortic and Beyond

Percutaneous Endoluminal Anatomical Bypass for a Ligated External lliac Artery
Tatsuya Nakama

4:00 - 4:08

Percutaneous Transapical Approach For Placing Arch And Other Devices: How Is It Possible
Ross Milner

4:08 - 5:00

Discussion

05:00 pm
Close of Symposium
VERVE Symposium: Room 2
08:00 - 09:30 am
Session 2.11: Current and Emerging Embolisation Techniques

An Update on Treatment for Endoleaks
Jos Van den Berg

8:00 - 8:10

Anti-Reflux and Balloon Microcatheter Embolization – Game Changers?
Gerard Goh

8:10 - 8:40

Transcaval Endoleak Embolisation
Tilo Kolbel

8:40 - 8:50

Direct Stick Puncture Technique to Manage Endoleaks
TBC

8:50 - 9:00

Management of Pelvic Congestion Syndrome is More Than Just the Left Ovarian Vein
Sanjay Nadkarni

9:00 - 9:30

Discussion

09:30 - 11:00 am
Session 2.12: Venous Disease of the Lower Extremity

Preliminary Experience of Cyanoacrylate Closure – Single Centre Data
Stefania Roberts

9:30 - 9:40

Vena-Plug: Cyanoacrylate Beyond Truncal Ablation
Nabeel Ibrahim

9:40 - 9:50

Unanswered Questions on Thermal Ablation of Truncal Venous Incompetence
Irwin Mohan

9:50 - 10:00

A Practical Guide to Sclerotherapy
Stefania Roberts

10:00 - 11:00

Discussion

11:00 - 11:30 am
Morning Tea
11:30 - 01:00 pm
Session 2.13: The Current Landscape in Carotid Revascularisation

Current Considerations for Patient Centred Revascularisation Strategies: CAS vs CEA vs BMT
Michael Neale

11:30 - 11:38

New Devices and Techniques in Carotid Stenting
Andrew Bullen

11:38 - 11:46

An Update on the Vascular Quality Initiative (VQI), Transcervical Carotid Revascularization Surveillance Project 
Marc Shermerhorn

11:46 - 11:54

Use of TCAR in recently symptomatic patients: Is it safe?
Peter Schneider

11:54 - 12:02

Proximal Protection During CAS: Why it is the Superior Concept
Giancarlo Biamino

12:02 - 12:10

Transradial Carotid Artery Stenting
Ravish Sachar

12:10 - 1:00

Discussion

01:00 - 02:00 pm
Lunch